Nicox S.A. (NICXF)
USD 0.25
(0.0%)
USD 0.25
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 25.15 Million EUR | -2.96% |
| 2022 | 25.92 Million USD | 11.14% |
| 2021 | 23.32 Million USD | 50.25% |
| 2020 | 15.52 Million USD | 52.89% |
| 2019 | 10.15 Million USD | 18701.86% |
| 2018 | 54 Thousand EUR | 107.69% |
| 2017 | 26 Thousand EUR | -13.33% |
| 2016 | 30 Thousand EUR | -94.29% |
| 2015 | 525 Thousand EUR | 10.53% |
| 2014 | 475 Thousand EUR | 356.73% |
| 2013 | 104 Thousand EUR | -8.77% |
| 2012 | 114 Thousand EUR | 96.55% |
| 2011 | 58 Thousand EUR | -30.12% |
| 2010 | 83 Thousand EUR | 1283.33% |
| 2009 | 6000.00 EUR | -53.85% |
| 2008 | 13 Thousand EUR | -31.58% |
| 2007 | 19 Thousand EUR | -44.12% |
| 2006 | 34 Thousand EUR | 70.0% |
| 2005 | 20 Thousand EUR | 566.67% |
| 2004 | 3000.00 EUR | -66.67% |
| 2003 | 9000.00 EUR | -75.0% |
| 2002 | 36 Thousand EUR | -57.65% |
| 2001 | 85 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q4 | 25.15 Million EUR | 0.0% |
| 2023 Q1 | 18.38 Million EUR | -29.09% |
| 2023 Q2 | 20.92 Million USD | 13.84% |
| 2023 FY | 25.15 Million EUR | -2.96% |
| 2022 Q2 | 21.16 Million EUR | -7.71% |
| 2022 Q4 | 25.92 Million USD | 26.91% |
| 2022 FY | 25.92 Million USD | 11.14% |
| 2022 Q1 | 22.93 Million EUR | 11.76% |
| 2022 Q3 | 20.42 Million EUR | -3.5% |
| 2021 Q3 | 24.5 Million EUR | 59.47% |
| 2021 Q1 | 18.79 Million EUR | 48.13% |
| 2021 Q2 | 15.36 Million EUR | -18.23% |
| 2021 FY | 23.32 Million USD | 50.25% |
| 2021 Q4 | 20.52 Million EUR | -16.27% |
| 2020 Q2 | 13.72 Million EUR | -15.2% |
| 2020 FY | 15.52 Million USD | 52.89% |
| 2020 Q1 | 16.18 Million EUR | 78.95% |
| 2020 Q3 | 15.74 Million EUR | 14.73% |
| 2020 Q4 | 12.68 Million EUR | -19.43% |
| 2019 Q4 | 9.04 Million EUR | -18.39% |
| 2019 FY | 10.15 Million USD | 18701.86% |
| 2019 Q3 | 11.08 Million EUR | 60.14% |
| 2019 Q2 | 6.92 Million EUR | -10.85% |
| 2019 Q1 | 7.76 Million EUR | 14276.52% |
| 2018 Q3 | 62.68 Thousand EUR | 3.24% |
| 2018 Q2 | 60.71 Thousand EUR | -5.21% |
| 2018 FY | 54 Thousand EUR | 107.69% |
| 2018 Q1 | 64.05 Thousand EUR | 105.35% |
| 2018 Q4 | 54 Thousand EUR | -13.86% |
| 2017 Q4 | 31.19 Thousand EUR | 1.51% |
| 2017 Q3 | 30.72 Thousand EUR | 58.26% |
| 2017 Q2 | 19.41 Thousand EUR | 7.06% |
| 2017 FY | 26 Thousand EUR | -13.33% |
| 2017 Q1 | 18.13 Thousand EUR | -39.54% |
| 2016 FY | 30 Thousand EUR | -94.29% |
| 2016 Q4 | 30 Thousand EUR | -10.97% |
| 2016 Q3 | 33.69 Thousand EUR | -13.59% |
| 2016 Q2 | 39 Thousand EUR | -12.19% |
| 2016 Q1 | 44.41 Thousand EUR | -91.54% |
| 2015 Q3 | 585.9 Thousand EUR | 115.41% |
| 2015 FY | 525 Thousand EUR | 10.53% |
| 2015 Q4 | 525 Thousand EUR | -10.39% |
| 2015 Q2 | 272 Thousand EUR | -98.72% |
| 2015 Q1 | 21.24 Million EUR | 4372.43% |
| 2014 Q3 | 599.48 Thousand EUR | 46.93% |
| 2014 Q1 | 562.17 Thousand EUR | 440.55% |
| 2014 Q2 | 408 Thousand EUR | -27.42% |
| 2014 FY | 475 Thousand EUR | 356.73% |
| 2014 Q4 | 475 Thousand EUR | -20.76% |
| 2013 FY | 104 Thousand EUR | -8.77% |
| 2013 Q4 | 104 Thousand EUR | -13.33% |
| 2013 Q3 | 120 Thousand EUR | 11.11% |
| 2013 Q2 | 108 Thousand EUR | 3.85% |
| 2013 Q1 | 104 Thousand EUR | -8.77% |
| 2012 Q3 | 58 Thousand EUR | 26.09% |
| 2012 Q4 | 114 Thousand EUR | 96.55% |
| 2012 FY | 114 Thousand EUR | 96.55% |
| 2012 Q1 | 58 Thousand EUR | 0.0% |
| 2012 Q2 | 46 Thousand EUR | -20.69% |
| 2011 Q3 | 65 Thousand EUR | -8.45% |
| 2011 Q4 | 58 Thousand EUR | -10.77% |
| 2011 Q1 | 76 Thousand EUR | -8.43% |
| 2011 Q2 | 71 Thousand EUR | -6.58% |
| 2011 FY | 58 Thousand EUR | -30.12% |
| 2010 Q3 | 90 Thousand EUR | 104.55% |
| 2010 Q2 | 44 Thousand EUR | 1000.0% |
| 2010 Q1 | 4000.00 EUR | 0.0% |
| 2010 FY | 83 Thousand EUR | 1283.33% |
| 2010 Q4 | 83 Thousand EUR | -7.78% |
| 2009 FY | 6000.00 EUR | -53.85% |
| 2008 FY | 13 Thousand EUR | -31.58% |
| 2007 FY | 19 Thousand EUR | -44.12% |
| 2006 FY | 34 Thousand EUR | 70.0% |
| 2005 FY | 20 Thousand EUR | 566.67% |
| 2004 FY | 3000.00 EUR | -66.67% |
| 2003 FY | 9000.00 EUR | -75.0% |
| 2002 FY | 36 Thousand EUR | -57.65% |
| 2001 FY | 85 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bioxytran, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -20.297% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -314312.5% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -1332.828% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -42792.466% |
| Marizyme, Inc. | 667.12 Thousand USD | -3670.335% |
| Genus plc | 228.2 Million USD | 88.978% |
| Pharming Group N.V. | 166.1 Million USD | 84.857% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -456231.64% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -1038.145% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -1692.885% |
| IMV Inc. | 27.39 Million USD | 8.196% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -363.523% |
| ONE Bio Corp. | 592.19 Thousand USD | -4147.397% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 54.771% |
| Mesoblast Limited | 100.29 Million USD | 74.921% |
| MultiCell Technologies, Inc. | 36.43 USD | -69044643.343% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -1029.964% |
| Genscript Biotech Corporation | 287.12 Million USD | 91.24% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1947.688% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -99322.902% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -1224.91% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -14589.599% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -7711.491% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.776% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -4435.423% |
| Enzolytics Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -15218.048% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -63.821% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -23.833% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -16668.667% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -564374.865% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -19814.966% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -10869.903% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -204.368% |
| Kadimastem Ltd | 229.69 Thousand USD | -10850.799% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -9369.008% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -2363903.759% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -16711.929% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -16711.929% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 445 Thousand USD | -5552.36% |
| CytoDyn Inc. | 141 Thousand USD | -17739.007% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -31341.25% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -221.651% |
| SYBLEU INC | 300 Thousand USD | -8284.333% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -6715.626% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -208.626% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -5403.939% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -2066.494% |
| PureTech Health plc | 18.25 Million USD | -37.825% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -16668.667% |
| IXICO plc | 275 Thousand USD | -9046.545% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -112.459% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 4.394% |
| CSL Limited | 11.23 Billion USD | 99.776% |
| Cellectis S.A. | 36.21 Million USD | 30.538% |